NanoGroup

What NanoGroup does

NanoGroup S.A. is a publicly listed Polish biotechnology holding company (Warsaw Stock Exchange ticker: NNG) that develops nanotechnology-based medical products through four wholly-owned operating subsidiaries: nanoSanguis (organ perfusion and blood substitutes), nanoVelos (polysaccharide nanoparticles for targeted cancer therapy), nanoTHEA (radiopharmaceuticals), and Doto Medical (aptamer-based blood filtration). The company's lead asset, the NanOX System, pairs the NanOX Recovery Box — the first dedicated normothermic kidney perfusion device on the market — with NanOX 4 Kidney, a synthetic perfluorocarbon-based perfusion fluid (Class III medical device) that transports oxygen and carbon dioxide during extracorporeal organ preservation. Beyond transplantation, the portfolio includes pharmaceutical candidates such as AUX-001 for chronic angina (FDA 505(b)(2) pathway, US-priority), PolEpi (epirubicin-polysaccharide conjugate for ovarian cancer), blood substitute programs, dextran conjugates, and radiotherapeutics.

NanoGroup monetizes through a multi-stream model that combines future medical device sales (hardware plus consumables), licensing and partnership agreements, and strategic equity investments. Commercial go-to-market relies on direct enterprise sales to transplant centers, hospitals and dialysis providers, augmented by distribution partnerships for global reach; product partnering windows are concentrated in Q4 2026 – Q1 2027 for the NanOX system, with a stated goal of signing a minimum of two large partnership agreements as a source of predictable, recurring revenue. The company is pre-revenue: the NanOX Recovery Box is in CE certification targeted for December 2026, NanOX 4 Kidney certification is planned for 2029, and AUX-001 is at Phase 1b. The business is currently sustained by public-market equity (a 24.5M PLN Series N emission completed October 2025 – February 2026), non-dilutive grants (22.8M PLN from FENG for NanOX 4 Kidney, 8.2M PLN from FENG STEP for the aptamer bioadsorber, 2.0M PLN from ABM for oncology), and capital recycling through strategic stakes, most notably the 7.5M PLN investment in Auxilius Pharma (23.08%) that is progressing to a binding share-exchange agreement signed in June 2026 to reach 100% ownership.

Name

NanoGroup

Legal name

NanoGroup S.A.

Website

https://nanogroup.eu

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

NanoGroup S.A. is a Polish listed biotech holding company developing nanotechnology-based medical products including organ perfusion devices, synthetic perfusion fluids, targeted cancer therapies, and aptamer filtration platforms for transplant, dialysis, and oncology markets.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Nanomedicine

NAICS

Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Organ perfusion devices
• Nanomedicine platforms
• Targeted drug delivery
• Radiopharmaceuticals oncology
• Aptamer filtration technology

Headquarters

HQ city

Rakowiec

HQ country

Poland

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Revenue from sales of medical devices including NanOX Recovery Box (Class 2b device) and perfusion sets (Class 2a). The device is planned for commercial availability after certification, with partnering agreements targeted for Q4 2026 – Q1 2027.
2. Perfusion Fluid Sales: Sales of NanOX 4 Kidney synthetic perfusion fluid (Class 3 medical device). The fluid is being developed for certification in 2029 and represents a consumable revenue stream for organ preservation.
3. Licensing and Partnering Agreements: Revenue from strategic partnership agreements for NanOX system and AUX-001 drug. The strategy targets signing minimum 2 large partnership agreements as a source of predictable and recurring revenue.
4. Investment Returns: Capital gains from strategic investments in portfolio companies including Auxilius Pharma. Investment strategy aims to participate in future revenues of partners through equity stakes.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

NanoGroup develops nanotechnology-based medical products across four subsidiaries: the NanOX System combining a dedicated normothermic kidney perfusion device (NanOX Recovery Box) with synthetic perfusion fluid (NanOX 4 Kidney) for organ transplantation; polysaccharide nanoparticle drug delivery systems for targeted cancer therapy; radiopharmaceuticals for oncology diagnostics and treatment; and aptamer-based filtration devices for dialysis and transplantology. The company also holds a stake in Auxilius Pharma developing AUX-001, an improved form of Nicorandil for chronic angina via the FDA 505(b)(2) pathway.

Product overview

NanoGroup is a biotechnology group developing multiple nanotechnology-based medical products across subsidiaries. The portfolio includes the integrated NanOX System (comprising NanOX Recovery Box device and NanOX 4 Kidney perfusion fluid) for organ transplantation, pharmaceutical products like AUX-001 for cardiovascular disease and PolEpi for cancer, and platform technologies including polysaccharide nanoparticle delivery systems (via NanoVelos), radiopharmaceuticals (via NanoThea), and aptamer-based filtration (via dotoMedical). The company also develops blood substitutes and dextran conjugate therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• nanoSanguis: Subsidiary focused on respiratory gas transport systems including blood substitutes and the NanoOX system for organ perfusion and transplantation medicine
• nanoVelos
• nanoTHEA
• Doto Medical

Products and services

• NanOX Recovery Box First dedicated normothermic kidney perfusion device on the market, enabling extracorporeal kidney perfusion with continuous monitoring for hypothermic and normothermic perfusion applications.
• NanOX 4 Kidney Synthetic perfusion fluid (Class III medical device) dedicated to ex-vivo organ preservation, maintaining the key respiratory function of blood through perfluorocarbon nanoparticles (nanorespirocytes) that transport oxygen and carbon dioxide.
• NanOX System Integrated solution for normothermic kidney perfusion consisting of the NanOX Recovery Box device, NanOX 4 Kidney perfusion fluid, and a single-use perfusion set, designed to double the possible transplant market and reduce costs for dialyzed patients.
• AUX-001 Improved form of Nicorandil for treatment of chronic angina pectoris, developed via the FDA 505(b)(2) regulatory pathway with priority target for the US market as part of the Value Added Medications portfolio.
• PolEpi Epirubicin-based drug candidate using polysaccharide carrier technology for ovarian cancer therapy, providing precise drug delivery with reduced side effects.
• Aptamer-based Bioadsorber Filter device using aptamer technology to selectively capture pro-inflammatory cytokines (TNF-alpha and IL-6) from perfusion fluids, designed as an additional element of an extracorporeal kidney perfusion dialysis system.
• Blood Substitute Temporary blood substitute based on perfluorocarbon nano-emulsions to address critical blood shortage, overcoming the 40-day shelf life limitation of donor blood through synthetic production.
• Dextran Conjugates Novel dextran-based conjugates for targeted anticancer therapy combining cytostatic drug, dextran carrier, and targeting factor for selective tumor cell delivery.

Quantifiable outcome

• 164 people die daily waiting for kidney transplants globally
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• SyVento sp. z o.o.coreImplementation/ SI/ Consulting Partner · 13 May 2026Contract development and manufacturing partnership for NanOX 4 Kidney perfusion fluid. SyVento provides industrial development and manufacturing in ISO 13485 and GMP standards. Total contract value exceeds 3.9 million PLN. Includes process scaling, optimization, validation, production of preclinical and clinical batches, analytics, quality control, and technical documentation preparation.
• Pure Biologics S.A.coreTechnology or Integration · 1 June 2025Acquisition of aptamer platform technology including full intellectual property rights (patents PL239946B1, EP3350195B1, US10450673) and Doto Medical company. Transaction strengthened R&D capabilities and expanded technology portfolio in diagnostics, blood filtration, and targeted therapies.
• Gdański Uniwersytet Medyczny (Medical University of Gdańsk)coreStrategic or Co-development PartnerResearch partner conducting ex vivo studies on NanOX 4 Kidney perfusion fluid. Performed perfusion studies and biochemical, metabolomic, and histopathological analyses on isolated rat kidneys in DCD model.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• TransMedics Group: TransMedics is a US-listed medical technology company and the commercial leader in normothermic organ perfusion systems (Organ Care System). Direct peer to NanoOX Recovery Box given identical target use case (ex-vivo organ preservation for transplantation) and similar clinical positioning.
• OrganOx: UK-based medical device company developing normothermic organ perfusion technology (metra device) for liver and kidney transplantation. Directly comparable to NanoOX Recovery Box in target application, technology approach, and customer base of transplant centers.
• XVIVO Perfusion: Swedish-listed medtech company specializing in organ preservation and perfusion technologies for thoracic and abdominal organ transplantation. Direct competitor in the same transplantology market, with established products including XPS and Perfadex solutions.
• Organ Recovery Systems: US-based company specializing in organ preservation technologies including the LifePort Kidney Transporter for hypothermic machine perfusion. Direct competitor to NanoOX system in kidney preservation, though focused on hypothermic rather than normothermic perfusion.
• Pure Biologics: Polish biotech company from which NanoGroup acquired the aptamer platform and Doto Medical in June 2025. Comparable as Polish-listed biotech developing aptamer-based therapeutic and diagnostic platforms with similar scientific foundation.
• Bridge to Life: US-based supplier of organ preservation solutions including Belzer UW and IGL cold storage solutions used in kidney transplantation. Comparable to NanOX 4 Kidney perfusion fluid in target market and product category.

Broad incumbents

• Pfizer: Large global pharmaceutical company with cardiovascular franchise and historical leadership in chronic angina therapeutics. Comparable as broad incumbent with established sales channels and cardiovascular expertise that could partner with or compete against AUX-001.
• AstraZeneca: Global pharmaceutical company with major cardiovascular franchise and oncology portfolio. Relevant as broad incumbent with relevant therapeutic area overlap to NanoGroup's AUX-001 cardiovascular and oncology candidates, plus existing consulting relationships with NanoGroup's founder.
• Celator Pharmaceuticals (Jazz Pharmaceuticals): Specialty pharmaceutical company with oncology drug delivery platforms (liposomal formulations). Comparable as broader specialty pharma developing improved formulations of existing drugs, similar to NanoGroup's AUX-001 (improved Nicorandil) approach using FDA 505(b)(2) pathway.
• Lantheus Holdings: US-listed radiopharmaceutical company with established portfolio of diagnostic and therapeutic radiopharmaceuticals. Comparable to NanoThea subsidiary in radiopharmaceutical focus area, though at much larger commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoGroup